Oncolytics Biotech is trading 5.94% up at $0.79, with no clear company-specific catalyst identified for September 14, 2026.
- The latest announcement, dated September 10, reported positive preclinical results combining pelareorep with a pan-RAS inhibitor in colorectal cancer; available coverage does not directly link it to today’s move.
- The broader market is moving lower, so global sentiment does not explain the gain.
- The move appears unexplained intraday pending further disclosures.